SCHEMBL2916705

SCHEMBL2916705

Cc1ccc(Nc2ncc3cccc(C)c3n2)cc1O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.52
SYK P43405 2/20 0.48
MAPK10 P53779 3/20 0.46
JUN P05412 1/20 0.46
CDK4 P11802 2/20 0.45
CDK2 P24941 2/20 0.45
CDK1 P06493 1/20 0.45
CCNB1 P14635 1/20 0.45
CCND1 P24385 1/20 0.45
CCNE1 P24864 1/20 0.45
PKMYT1 Q99640 1/20 0.43
EGFR P00533 1/20 0.43
AURKA O14965 3/20 0.43
MAP3K5 Q99683 1/20 0.41
SRC P12931 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
JAK3 P52333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2916276 0.88 SYK (0.45) KDRSYKMAPK10JUNCDK4
SCHEMBL2919611 0.87 L3MBTL1 (0.51) SYKMAPK10JUNCDK4CDK2
SCHEMBL2913212 0.86 JAK2 (0.49) KDRSYKMAPK10JUNCDK4
SCHEMBL2922769 0.85 SYK (0.67) KDRSYKCDK4CDK2CDK1
SCHEMBL12999378 0.85 AURKA (0.60) SYKMAPK10CDK4CDK2CDK1
SCHEMBL2912369 0.80 SYK (0.56) SYKCDK4CDK2SRCJAK2
SCHEMBL2913599 0.80 KDR (0.56) KDRSYKCDK4CDK2CDK1
SCHEMBL2911814 0.80 MAPK10 (0.53) KDRSYKMAPK10JUNCDK4
SCHEMBL12999377 0.80 ABL1 (0.58) SYKCDK4CDK2EGFRAURKA
SCHEMBL12999380 0.79 JAK2 (0.52) KDRMAPK10JUNCDK4CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K KDR 1592/4885SYK 724/4885MAPK10 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.